Evidence method
Level · gp.fundamentals.debt_to_revenue
373.34% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Jun 30, 2016
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001144204-16-116629General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.29% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
60.57% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
79.94% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
62.36% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
16.57% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
2.44% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
7.07% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 560.44%
- Current
- 373.34%
- Delta
- -187.10%
- Previous
- 6.66%
- Current
- 2.29%
- Delta
- -4.37%
- Previous
- 9.34%
- Current
- 60.57%
- Delta
- 51.23%
- Previous
- 67.73%
- Current
- 79.94%
- Delta
- 12.21%
- Previous
- 83.41%
- Current
- 62.36%
- Delta
- -21.05%
- Previous
- 27.57%
- Current
- 16.57%
- Delta
- -10.99%
- Previous
- 4.70%
- Current
- 2.44%
- Delta
- -2.26%
- Previous
- 5.38%
- Current
- 7.07%
- Delta
- 1.70%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_DECREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIP MARGIN_DECREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIP SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.